Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹4,750 Cr
down ₹160 Cr vs Jan 2022
- Stocks held
- 24
- unchanged
- Top 10 weight
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In February 2022 it disclosed 24 stocks worth ₹4,750 Cr, down ₹160 Cr from Jan 2022. Its largest positions were Sun Pharmaceutical Industries Limited (13.0%), Cipla Limited (8.8%), Dr. Reddy's Laboratories Limited (8.5%); the ten largest together made up 73.1% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 75.8% of its equity. Cash and debt stood at 1.3%. Compared with Jan 2022 the fund entered 0 new stocks and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
94%
Top-10 weight is higher than 94% of peers
Breadth
7%
Holds more stocks than 7% of peers
Cash
15%
Holds more cash than 15% of peers
What these mean: concentration · cash
Holdings in February 2022
Download CSVEvery line the fund disclosed, with the change against Jan 2022. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 12.97% | up 0.56 pts | ₹616 Cr | up ₹6.9 Cr | Added |
| Cipla Limited | 8.76% | up 0.10 pts | ₹416 Cr | down ₹9 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 8.47% | down 0.21 pts | ₹402 Cr | down ₹23.7 Cr | Trimmed |
| Divi's Laboratories Limited | 7.63% | up 0.65 pts | ₹363 Cr | up ₹19.5 Cr | Added |
| Lupin Limited | 6.60% | down 1.17 pts | ₹313 Cr | down ₹68.1 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 6.50% | up 0.30 pts | ₹309 Cr | up ₹4.4 Cr | Added |
| Torrent Pharmaceuticals Limited | 6.08% | up 0.37 pts | ₹289 Cr | up ₹8.2 Cr | Added |
| Apollo Hospitals Enterprise Limited | 6.07% | down 0.29 pts | ₹289 Cr | down ₹23.8 Cr | Trimmed |
| Aurobindo Pharma Limited | 5.27% | down 0.29 pts | ₹250 Cr | down ₹22.7 Cr | Trimmed |
| Abbott India Limited | 4.76% | up 0.54 pts | ₹226 Cr | up ₹19 Cr | Added |
| Gland Pharma Limited | 3.73% | down 0.21 pts | ₹177 Cr | down ₹16.1 Cr | Trimmed |
| Fortis Healthcare Limited | 3.54% | down 0.23 pts | ₹168 Cr | down ₹17 Cr | Trimmed |
| Thyrocare Technologies Limited | 3.38% | down 0.32 pts | ₹161 Cr | down ₹21.2 Cr | Trimmed |
| Sanofi India Limited | 3.29% | down 0.03 pts | ₹156 Cr | down ₹6.6 Cr | Trimmed |
| Indoco Remedies Limited | 1.93% | up 0.10 pts | ₹91.5 Cr | up ₹1.6 Cr | Added |
| Zydus Lifesciences Limited | 1.90% | down 0.17 pts | ₹90.1 Cr | down ₹11.5 Cr | Trimmed |
| Pfizer Limited | 1.64% | up 0.01 pts | ₹77.8 Cr | down ₹2.2 Cr | Trimmed |
| Vijaya Diagnostic Centre Limited | 1.55% | down 0.14 pts | ₹73.7 Cr | down ₹9.5 Cr | Trimmed |
| JB Chemicals & Pharmaceuticals Limited | 1.35% | up <0.01 pts | ₹64.2 Cr | down ₹1.9 Cr | Trimmed |
| Cash, TREPS & receivables | 1.30% | up 0.89 pts | ₹61.9 Cr | up ₹41.5 Cr | Added |
| Alkem Laboratories Limited | 1.29% | down 0.06 pts | ₹61.3 Cr | down ₹4.9 Cr | Trimmed |
| Orchid Pharma Limited | 0.58% | down 0.19 pts | ₹27.3 Cr | down ₹10 Cr | Trimmed |
| Healthcare Global Enterprises Limited | 0.48% | down 0.02 pts | ₹22.8 Cr | down ₹2 Cr | Trimmed |
| Tarsons Products Limited | 0.47% | down 0.07 pts | ₹22.5 Cr | down ₹4.1 Cr | Trimmed |
| Jubilant Pharmova Limited | 0.46% | down 0.12 pts | ₹21.9 Cr | down ₹6.7 Cr | Trimmed |
What changed, Jan 2022 to Feb 2022
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Divi's Laboratories Limitedup ₹19.5 Cr (+0.65% pts)
- Abbott India Limitedup ₹19 Cr (+0.54% pts)
- Torrent Pharmaceuticals Limitedup ₹8.2 Cr (+0.37% pts)
- Sun Pharmaceutical Industries Limitedup ₹6.9 Cr (+0.56% pts)
- Narayana Hrudayalaya Limited ₹4.4 Cr (+0.30% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jan 2022, the weight rose most in Pharmaceuticals & Biotechnology (+0.5 pts) and Pharmaceuticals (+0.1 pts), and fell most in Healthcare Services (−0.5 pts).
- Pharmaceuticals & Biotechnology75.3% → 75.8%+0.5 pts
- Pharmaceuticals1.8% → 2.0%+0.1 pts
- Healthcare Services22.3% → 21.8%−0.5 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Feb 2021 | Aug 2021 | Nov 2021 | Jan 2022 | Feb 2022 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 79.0% | 73.6% | 74.9% | 75.3% | 75.8% |
| Healthcare Services | 18.3% | 23.7% | 22.7% | 22.3% | 21.8% |
| Pharmaceuticals | 2.4% | 2.2% | 1.8% | 1.8% | 2.0% |
| Healthcare Equipment & Supplies | — | — | 0.6% | 0.5% | 0.5% |
Allocation in Feb 2022change vs Jan 2022
- Pharmaceuticals & Biotechnology (16)75.8%▲ 0.5 pts
- Healthcare Services (6)21.8%▼ 0.5 pts
- Pharmaceuticals (1)2.0%▲ 0.1 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Feb 2022
1.3%
▲ 0.9 pts vs Jan 2022
- Cash alone
- 1.3%
- cash and net receivables
- A year earlier
- 0.9%
- Feb 2021 · now ▲ 0.4 pts
- Last 12 months
- 0.4% – 5.9%
- lowest to highest · record 5.9% in May 2021
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.